Want to join the conversation?
$ALXN received FDA approval for bone disease therapy. Strensiq, which will treat perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP), will be available commercially by Oct. 27. This was based on data from 4 clinical trials and supporting extension trials. The most commonly reported adverse events observed were injection site reactions.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.